Mesenchymal stromal cells and regulatory T cells: The Yin and Yang of peripheral tolerance

Immunology and Cell Biology

Volumn 91, Issue 1, 2013, Pages 12-18

  Burr, Stephen P ^a,c   Dazzi, Francesco ^b   Garden, Oliver A ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

autoimmune disease; graft versus host disease; immunoregulation

Indexed keywords

HEME OXYGENASE 1; HLA G ANTIGEN; HLA G5 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

APOPTOSIS; CELL CONTACT; CELL INTERACTION; CYTOKINE RESPONSE; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MESENCHYMAL STROMA CELL; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; DINOPROSTONE; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TISSUE THERAPY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84872168547     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.60     Document Type: Review

References (109)

1. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974; 17: 331-340.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
3. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
4. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61: 364-370. (Pubitemid 30620221)
5. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295. (Pubitemid 35471185)
6. Demircan PC, Sariboyaci AE, Unal ZS, Gacar G, Subasi C, Karaoz E. Immunoregulatory effects of human dental pulp-derived stem cells on T cells: Comparison of transwell co-culture and mixed lymphocyte reaction systems. Cytotherapy 2011; 13: 1205-1220.
7. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213. (Pubitemid 43960310)
8. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: Proliferation, Oct4 expression, and plasticity. Stem Cells 2005; 23: 1105-1112. (Pubitemid 41377726)
9. Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N et al. Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 2010; 16: 3537-3546.
10. Noel D, Djouad F, Jorgense C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Investig Drugs 2002; 3: 1000-1004. (Pubitemid 36266786)
11. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
12. Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011; 33: 593-602.
13. Bassi EJ, Aita CA, Camara NO. Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? World J Stem Cells 2011; 3: 1-8.
14. Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-7973.
15. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010; 5: E10088.
16. Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. Scientific World J 2011; 11: 2391-2402.
17. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-1432. (Pubitemid 46239573)
18. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26: 279-289.
19. Chaperon EA, Selner JC, Claman HN. Migration of antibody-forming cells and antigen-sensitive precursors between spleen, thymus and bone marrow. Immunology 1968; 14: 553-561.
20. Dorf ME, Benacerraf B. Suppressor cells and immunoregulation. Annu Rev Immunol 1984; 2: 127-157.
21. Kronenberg M, Kraig E, Siu G, Kapp JA, Kappler J, Marrack P et al. Three T cell hybridomas do not contain detectable heavy chain variable gene transcripts. J Exp Med 1983; 158: 210-227. (Pubitemid 13073522)
22. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4 +CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160: 1212-1218. (Pubitemid 28093417)
23. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4 +CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253. (Pubitemid 32703119)
24. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79. (Pubitemid 33070208)
25. Weiner HL. Induction and mechanism of action of transforming growth factor-betasecreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-214. (Pubitemid 33070220)
26. Jonuleit H, Schmitt E. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol 2003; 171: 6323-6327. (Pubitemid 37532056)
27. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
28. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
29. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4 +CD25-naive T cells to CD4 +CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886. (Pubitemid 38032120)
30. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4 +CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172: 5149-5153. (Pubitemid 38542009)
31. Garden OA, Pinheiro D, Cunningham F. All creatures great and small: Regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol 2011; 11: 576-588.
32. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M et al. Immunologic self-tolerance maintained by CD25+CD4 + naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969-1980. (Pubitemid 28566059)
33. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: How do they suppress immune responses? Int Immunol 2009; 21: 1105-1111.
34. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-1041. (Pubitemid 44464736)
35. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Res Ther 2010; 1: 2.
36. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302-312.
37. Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J. Contactdependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol 2007; 35: 426-433.
38. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 2004; 103: 4619-4621. (Pubitemid 38745993)
39. Maby-El Hajjami H, Ame-Thomas P, Pangault C, Tribut O, DeVos J, Jean R et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: Role of indoleamine-2,3 dioxygenase. Cancer Res 2009; 69: 3228-3237.
40. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234. (Pubitemid 46053063)
41. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
42. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032. (Pubitemid 47258180)
43. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652-5657.
44. Zhang A, Wang Y, Ye Z, Xie H, Zhou L, Zheng S. Mechanism of TNF-alpha-induced migration and hepatocyte growth factor production in human mesenchymal stem cells. J Cell Biochem 2010; 111: 469-475.
45. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-4835.
46. Nasef A, Mazurier C, Bouchet S, Francois S, Chapel A, Thierry D et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253: 16-22.
47. Sioud M, Mobergslien A, Boudabous A, Floisand Y. Mesenchymal stem cellmediated T cell suppression occurs through secreted galectins. Int J Oncol 2011; 38: 385-390.
48. Choi YS, Jeong JA, Lim DS. Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppressive effect. Immunol Invest 2012; 41: 214-229.
49. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011; 66: 523-531.
50. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
51. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 2005; 90: 516-525. (Pubitemid 40592895)
52. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309-318. (Pubitemid 351221170)
53. Kim IY, Kim MM, Kim SJ. Transforming growth factor-beta: Biology and clinical relevance. J Biochem Mol Biol 2005; 38: 1-8. (Pubitemid 43025971)
54. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 +CD25(high) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
55. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184: 5885-5894.
56. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21-28.
57. Walker C, Kristensen F, Bettens F, deWeck AL. Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol 1983; 130: 1770-1773. (Pubitemid 13091632)
58. Rincon M, Tugores A, Lopez-Rivas A, Silva A, Alonso M, De Landazuri MO et al. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 1988; 18: 1791-1796. (Pubitemid 19011589)
59. Soontrapa K, Honda T, Sakata D, Yao C, Hirata T, Hori S et al. Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci USA 2011; 108: 6668-6673.
60. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-1379. (Pubitemid 44924495)
61. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
62. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 +CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
63. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19: 662-664. (Pubitemid 40471278)
64. Pae HO, Chung HT. Heme oxygenase-1: Its therapeutic roles in inflammatory diseases. Immune Netw 2009; 9: 12-19.
65. Xia ZW, Xu LQ, Zhong WW, Wei JJ, Li NL, Shao J et al. Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor-1. Am J Pathol 2007; 171: 1904-1914.
66. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193. (Pubitemid 28406294)
67. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372. (Pubitemid 29227522)
68. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophanderived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-468.
69. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9: 1069-1077.
70. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 6752-6761. (Pubitemid 43787857)
71. Zhao ZG, Xu W, Sun L, You Y, Li F, Li QB et al. Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest 2012; 41: 183-198.
72. Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-1962.
73. Larsen S, Lewis ID. Potential therapeutic applications of mesenchymal stromal cells. Pathology 2011; 43: 592-604.
74. Muller I, Lymperi S, Dazzi F. Mesenchymal stem cell therapy for degenerative inflammatory disorders. Curr Opin Organ Transplant 2008; 13: 639-644.
75. McMurchy AN, Bushell A, Levings MK, Wood KJ. Moving to tolerance: Clinical application of T regulatory cells. Semin Immunol 2011; 23: 304-313.
76. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Gregoire S et al. Ex vivo-expanded CD4 +CD25+ immunoregulatory T cells prevent graft-versus-host- disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 1266-1273. (Pubitemid 43099732)
77. Cao T, Soto A, Zhou W, Wang W, Eck S, Walker M et al. Ex vivo expanded human CD4 +CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol 2009; 258: 65-71.
78. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
79. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896. (Pubitemid 37211373)
80. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donorderived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120. (Pubitemid 44395028)
81. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-2591. (Pubitemid 44674320)
82. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181: 3933-3946.
83. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441. (Pubitemid 38586721)
84. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397. (Pubitemid 43847148)
85. Kollar K, Seifried E, Henschler R. Therapeutic potential of intravenously administered human mesenchymal stromal cells. Hamostaseologie 2011; 31: 269-274.
86. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744-755.
87. Uccelli A, Prockop DJ. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 2010; 22: 768-774.
88. Pistoia V, Raffaghello L. Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev Clin Immunol 2010; 6: 211-218.
89. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E et al. Adiposederived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27: 2624-2635.
90. Kim YH, Wee YM, Choi MY, Lim DG, Kim SC, Han DJ. Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 2011; 17: 697-708.
91. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006-1019.
92. Choi EW, Shin IS, Park SY, Park JH, Kim JS, Yoon EJ et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 2012; 64: 243-253.
93. Choi EW, Shin IS, Lee HW, Park SY, Park JH, Nam MH et al. Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med 2011; 13: 3-16.
94. Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011; 9: 181.
95. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 1187-1194.
96. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M et al. IFATS collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 2008; 26: 2705-2712.
97. Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M. Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. J Neurotrauma 2001; 18: 813-819. (Pubitemid 32769777)
98. Chen J, Li Y, Chopp M. Intracerebral transplantation of bone marrow with BDNF after MCAo in rat. Neuropharmacology 2000; 39: 711-716. (Pubitemid 30103675)
99. Sun J, Han ZB, Liao W, Yang SG, Yang Z, Yu J et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4 +CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing anti-and pro-inflammatory factors. Cell Physiol Biochem 2011; 27: 587-596.
100. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 2006; 24: 2466-2477.
101. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12.
102. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919-926. (Pubitemid 37543568)
103. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20: 1297-1308.
104. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844. (Pubitemid 37409409)
105. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371-379. (Pubitemid 46232791)
106. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 2008; 22: 593-599. (Pubitemid 351386730)
107. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4 + CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150. (Pubitemid 37173698)
108. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumourinfiltrating regulatory T cells stimulate mammary cancer metastasis through RANKLRANK signalling. Nature 2011; 470: 548-553.
109. Gajewski TF, Chesney J, Curriel TJ. Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol 2009; 7: 1-10; quiz 1-2.